Bexarotene topical

Drug Profile

Bexarotene topical

Alternative Names: Bexarotene gel; LGD 1069 topical; Targretin gel; Targretyn gel; Tarrexin gel

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Eisai Co Ltd
  • Class Antineoplastics; Benzoic acids; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists; Protein synthesis inhibitors; Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Discontinued Actinic keratosis; Alopecia areata; Atopic dermatitis; Basal cell cancer; Kaposi's sarcoma; Mycosis fungoides; Psoriasis

Most Recent Events

  • 15 Oct 2018 No development reported - Preregistration for Cutaneous T-cell lymphoma in Mexico (Topical)
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 22 Jun 2017 Bexarotene licensed to Ewopharma for commercialisation in Hungary and Poland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top